

Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

NCT06138743

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Arrowhead Pharmaceuticals
Enrollment	78 participants

Key Eligibility Criteria

Inclusion (5)

- Genetically confirmed diagnosis of DM1
- Clinician-assessed signs of DM1 including clinically apparent myotonia
- Onset of DM1 symptoms occurred after the age of 12 years
- Walk for at least 10 meters independently at Screening
- Subjects of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last dose of study drug, whichever is later. Subjects must not donate sperm or eggs during the study and for at least 90 days following the end of study or last dose of study drug whichever is later.

Exclusion (10)

- Inadequately controlled diabetes
- Confirmed diagnosis of congenital DM1
- Uncontrolled hypertension
- History of tibialis anterior (TA) biopsy within 3 months of Day 1 or planning to undergo TA biopsies during the study period
- Clinically significant cardiac, liver or renal disease
- ... and 5 more (see full listing online)

Locations (11 total)

Research Site, Liverpool, New South Wales, Australia
Research Site, Birtinya, Queensland, Australia
Research Site, Herston, Queensland, Australia
... and 8 more locations